Bivalent vaccine effectiveness, COVID booster schedule and Evusheld update with Sandra Fryhofer, MD


American Medical Association (AMA)

AMA Board Chair Sandra Fryhofer, MD, AMA’s liaison to the Advisory Committee on Immunization Practices (ACIP), and a member of ACIP’s COVID-19 Vaccine Workgroup, recaps the latest news from the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting. Topics include the vote on “harmonizing” strain composition for both COVID-19 primary vaccines and booster shots, as well as an update about the preliminary stroke risk signal for seniors who received a Pfizer booster. American Medical Association CXO Todd Unger hosts.

00:00 AMA Update for Jan. 31, 2023 01:01 Highlights from recent VRBPAC meeting 02:00 Vote to harmonize COVID-19 vaccines passes unanimously by FDA vaccine advisers 02:32 Novavax plans to deliver bivalent vaccines for 2023-2024 vaccination season, representatives say 03:00 What does “harmonizing vaccine strain composition” mean? 04:08 Will there be an annual COVID shot? Or new bivalent boosters this fall? 05:55 COVID vaccine development timeline: how long will a new vaccine take to make? 06:41 Would there be a standardized dose? (COVID-19 vaccine dosage) 08:07 Bivalent boosters protect against XBB.1.5 variant, CDC study shows 09:57 When will COVID vaccine changes go into effect? 10:38 Pfizer vaccine stroke risk 11:42 Why did FDA withdraw authorization for Evusheld? 12:34 Recommendations for immunocompromised patients 14:05 Current boosters effective against XBB 1.5 variant